Diana Danca’s practice primarily focuses on intellectual property and patent infringement matters with an emphasis on chemical, biotech, and pharmaceutical patent litigation, under the Hatch-Waxman Act and BPCIA. She has also conducted due diligence investigations related to merger and acquisitions, and has rendered opinions on patentability and patent infringement issues. Diana’s patent experience spans matters involving a wide range of technologies, including cancer, CNS, ophthalmic disease areas, drug delivery and formulations, small molecule, enantiomers, polymorphs, protein drug product, and protein chemistry and purification.
Before practicing law, Diana worked for several biotech companies as a medicinal chemist, designing and synthesizing novel compounds. She is the co-inventor of NINLARO®, a novel oral proteasome inhibitor approved in 2015 for the treatment of multiple myeloma, and the co-inventor of a kinase inhibitor that was tested in Phase I clinical trials. Diana is a co-inventor on several compound, formulation, and method of treatment pharmaceutical patents. She has also co-authored several scientific publications in the field of organic and medicinal chemistry.